Overview

Gene Location [1]
7q31.2
Pathway
Receptor tyrosine kinase/growth factor signaling
Variant Type
Amplification
Gene
MET

MET Amplification is present in 0.49% of AACR GENIE cases, with lung adenocarcinoma, conventional glioblastoma multiforme, colon adenocarcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma having the greatest prevalence [4].

Top Disease Cases with MET Amplification

Biomarker-Directed Therapies

Significance of MET Amplification in Diseases

Non-Small Cell Lung Carcinoma +

Malignant Solid Tumor +

Breast Carcinoma +

Colorectal Carcinoma +

Hepatocellular Carcinoma +

Gastric Adenocarcinoma +

Cancer +

Adenocarcinoma Of The Gastroesophageal Junction +

Head And Neck Squamous Cell Carcinoma +

Gastric Carcinoma +

Renal Cell Carcinoma +

Melanoma +

Squamous Cell Lung Carcinoma +

Glioblastoma +

Endometrial Carcinoma +

Non-Hodgkin Lymphoma +

Bladder Carcinoma +

Ewing Sarcoma +

Head And Neck Carcinoma +

Lymphoma +

Multiple Myeloma +

Osteosarcoma +

Ovarian Carcinoma +

Pancreatic Adenocarcinoma +

Pancreatic Carcinoma +

Prostate Carcinoma +

Urothelial Carcinoma +

Papillary Renal Cell Carcinoma +

Esophageal Carcinoma +

Lung Carcinoma +

Glioma +

Bile Duct Carcinoma +

Cholangiocarcinoma +

Soft Tissue Sarcoma +

Colorectal Adenocarcinoma +

Adrenal Cortex Carcinoma +

Aggressive Systemic Mastocytosis +

Alveolar Soft Part Sarcoma +

B-Cell Non-Hodgkin Lymphoma +

Bronchogenic Carcinoma +

Cervical Carcinoma +

Cervical Squamous Cell Carcinoma +

Chondrosarcoma +

Classical Hodgkin Lymphoma +

Clear Cell Sarcoma Of Soft Tissue +

Desmoid-Type Fibromatosis +

Diffuse Intrinsic Pontine Glioma +

Esophageal Squamous Cell Carcinoma +

Gallbladder Carcinoma +

Gliosarcoma +

Hematologic And Lymphocytic Disorder +

Hematopoietic And Lymphoid Malignancy +

Hematopoietic And Lymphoid System Neoplasm +

Hepatoblastoma +

High Grade Ovarian Serous Adenocarcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Liposarcoma +

Malignant Uterine Neoplasm +

Mast Cell Leukemia +

Medulloblastoma +

Mesothelioma +

Myelodysplastic Syndromes +

Myeloid Neoplasm +

Oropharyngeal Squamous Cell Carcinoma +

Pecoma +

Peritoneal Mesothelioma +

Rhabdomyosarcoma +

Small Cell Lung Carcinoma +

Systemic Mastocytosis With An Associated Hematological Neoplasm (SM-AHN) +

Thyroid Gland Carcinoma +

Thyroid Gland Medullary Carcinoma +

Undifferentiated Pleomorphic Sarcoma +

Wilms Tumor +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.